Psychedelic · MM120

Lysergide D-tartrate (MM120 / LSD)

Phase 3Definium Therapeutics, Inc. (DFTX)
  • Breakthrough Therapy

MindMed's (now Definium Therapeutics) pharmaceutically optimized lysergide (LSD) as an orally disintegrating tablet (MM120 ODT, rebranded DT120 ODT in Jan 2026). A classic serotonergic psychedelic given as a single monitored dose without adjunctive psychotherapy. Lead indication generalized anxiety disorder; also Phase 3 for MDD.

Also known as: MM120, DT120, Lysergide D-tartrate, LSD

Data current as of

Key facts

Modality
Psychedelic
Chemical class
Ergoline, Lysergamide, tryptamine
DEA schedule
Schedule I
Chemistry
Single enantiomer
Mechanism
5-HT2A Partial agonist
Highest phase
Phase 3
Lead indication
Generalized anxiety disorder
Developer
Definium Therapeutics, Inc. (DFTX)
Designations
Breakthrough Therapy
Trials
5 tracked · 1 recruiting · 120 sites
Next catalyst
Sep 2026 — Topline data (Generalized anxiety disorder)

Mechanism of action#

LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.

TargetActionAffinity
5-HT2AprimaryHTR2APartial agonistpKi 9.4ⓘ
5-HT1AHTR1AAgonistpKi 9ⓘ
5-HT2CHTR2CAgonistpKi 8.2ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology
Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset
OralSingle dose—
MM120 oral (Phase 2b)
Single oral dose; 25, 50, 100, or 200 µg freebase-equivalent studied in Phase 2b GAD; 100 µg selected as optimal for pivotal trials
OralSingle dose—

Development timeline#

Jan 24Jul 24Jan 25Jul 25Jan 26Jul 26Jan 27TodayPhase 31 Jan 2027 — upcoming — Phase 3 Haven study of DT120 ODT in PTSD expected to initiate in 20271 Sept 2026 — upcoming — Panorama, the second Phase 3 study of DT120 ODT in GAD: topline expected September 202612 Aug 2026 — readout (met) — Phase 3 Voyage topline: single-dose DT120 ODT meets primary in GAD (HAM-A −5.4 pts vs placebo at Week 12, p<0.0001)25 Jun 2026 — Financing — Definium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 program22 Jun 2026 — readout (met) — Phase 3 Emerge topline: single-dose DT120 ODT meets primary in MDD (MADRS −8.1 pts vs placebo at Week 6, p<0.0001)12 May 2026 — Trial started — First patient dosed in Ascend, the second Phase 3 pivotal study of DT120 ODT in MDD22 Apr 2026 — phase change — Definium Therapeutics announced expansion of the DT120 ODT program into PTSD with the planned Phase 3 'Haven' study (~200 participants, 1:1 DT120 ODT vs placebo, primary endpoint CAPS-5 at Week 8), initiation expected in 2027. No NCT registered as of this record.22 Apr 2026 — Enrollment complete — Voyage (Phase 3, DT120 ODT in GAD) completes enrollment with 214 participants22 Apr 2026 — Enrollment complete — Emerge (Phase 3, DT120 ODT in MDD) completes enrollment with 149 participants12 Jan 2026 — Corporate rebrand / name change — Mind Medicine (MindMed) rebrands as Definium Therapeutics1 Sept 2025 — phase change — Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.29 Jan 2025 — phase change — First patient dosed in Panorama (NCT06809595), second pivotal Phase 3 GAD study.11 Dec 2024 — phase change — First patient dosed in Phase 3 Voyage (NCT06741228) — first-ever Phase 3 of LSD.3 Aug 2023 — Licensing deal — Catalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)Phase 27 Mar 2024 — phase change — FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.4 Dec 2023 — phase change — Phase 2a proof-of-concept ADHD study (NCT05200936 / MMED007) completed (study completion date 2023-12-04; primary completion 2023-11-06).Discontinued19 Mar 2025 — readout (missed) — Phase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145)
Phase change Readout Event UpcomingHover a marker for details.
Phase 3Aug 2023 – Jan 2027
  1. UpcomingPhase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027Post-traumatic stress disorder↗
  2. UpcomingPanorama, the second Phase 3 study of DT120 ODT in GAD: topline expected September 2026Generalized anxiety disorder↗
  3. metPhase 3 Voyage topline: single-dose DT120 ODT meets primary in GAD (HAM-A −5.4 pts vs placebo at Week 12, p<0.0001)Generalized anxiety disorder↗
  4. FinancingDefinium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 program↗
  5. metPhase 3 Emerge topline: single-dose DT120 ODT meets primary in MDD (MADRS −8.1 pts vs placebo at Week 6, p<0.0001)Major depressive disorder↗
  6. Trial startedFirst patient dosed in Ascend, the second Phase 3 pivotal study of DT120 ODT in MDDMajor depressive disorder↗
  7. Definium Therapeutics announced expansion of the DT120 ODT program into PTSD with the planned Phase 3 'Haven' study (~200 participants, 1:1 DT120 ODT vs placebo, primary endpoint CAPS-5 at Week 8), initiation expected in 2027. No NCT registered as of this record.Post-traumatic stress disorder↗
  8. Enrollment completeVoyage (Phase 3, DT120 ODT in GAD) completes enrollment with 214 participantsGeneralized anxiety disorder↗
  9. Enrollment completeEmerge (Phase 3, DT120 ODT in MDD) completes enrollment with 149 participantsMajor depressive disorder↗
  10. Corporate rebrand / name changeMind Medicine (MindMed) rebrands as Definium Therapeutics↗
  11. Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.Major depressive disorder
  12. First patient dosed in Panorama (NCT06809595), second pivotal Phase 3 GAD study.Generalized anxiety disorder↗
  13. First patient dosed in Phase 3 Voyage (NCT06741228) — first-ever Phase 3 of LSD.Generalized anxiety disorder↗
  14. Licensing dealCatalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)↗
DiscontinuedMar 2025
  1. missedPhase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145)Attention-deficit/hyperactivity disorder↗
Phase 2Dec 2023 – Mar 2024
  1. FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.Generalized anxiety disorder↗
  2. Phase 2a proof-of-concept ADHD study (NCT05200936 / MMED007) completed (study completion date 2023-12-04; primary completion 2023-11-06).Attention-deficit/hyperactivity disorder

Lysergide D-tartrate (MM120 / LSD) for Generalized anxiety disorder#

Phase 3ActiveGeneralized anxiety disorder indication →

MM120 (DT120) for generalized anxiety disorder — lead program. FDA Breakthrough Therapy granted 7 Mar 2024 on the Phase 2b dose-finding study (NCT05407064; 100 ug gave -7.7 HAM-A vs placebo at Week 12, Cohen's d 0.81). Two pivotal Phase 3 GAD studies underway: Voyage (NCT06741228) and Panorama (NCT06809595), both active, primary completion 2026. The same compound is also Phase 3 for MDD (Emerge, NCT06941844).

Readouts

  • Sep 2026AnticipatedTopline data

    Panorama, the second Phase 3 study of DT120 ODT in GAD: topline expected September 2026 ↗

  • 2026-08-12ReportedTopline datamet

    Phase 3 Voyage topline: single-dose DT120 ODT meets primary in GAD (HAM-A −5.4 pts vs placebo at Week 12, p<0.0001) ↗

Lysergide D-tartrate (MM120 / LSD) for Major depressive disorder#

Phase 3RecruitingMajor depressive disorder indication →

MM120 (DT120) for major depressive disorder — second indication after the lead GAD program. Phase 3 'Emerge' study (NCT06941844) evaluates a single dose for MDD. Builds on MM120's Phase 2b anxiety data and the GAD Phase 3 program (Voyage/Panorama).

Readouts

  • 2026-06-22ReportedTopline datamet

    Phase 3 Emerge topline: single-dose DT120 ODT meets primary in MDD (MADRS −8.1 pts vs placebo at Week 6, p<0.0001) ↗

Lysergide D-tartrate (MM120 / LSD) for Attention-deficit/hyperactivity disorder#

DiscontinuedDiscontinuedAttention-deficit/hyperactivity disorder indication →

MM120 (lysergide / LSD; DT120) for attention-deficit/hyperactivity disorder — a deliberately tracked NEGATIVE program. The single Phase 2a proof-of-concept study (NCT05200936, study code MMED007) tested a low-dose 'microdosing' regimen (20 ug twice weekly for 6 weeks) and MISSED its primary endpoint: the change in Adult ADHD Investigator Symptom Rating Scale (AISRS) at 6 weeks did not differ from placebo (LSD -7.1 vs placebo -8.9 points; p=0.7145). Repeated low-dose LSD was safe/tolerable but showed no efficacy advantage. Results were published in JAMA Psychiatry (June 2025). MindMed (now Definium Therapeutics) did not advance MM120 to Phase 3 in ADHD, focusing instead on generalized anxiety disorder (lead) and major depressive disorder; the ADHD program is treated as discontinued.

Readouts

  • 2025-03-19ReportedFull resultsmissedNCT05200936

    Phase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145) ↗

Lysergide D-tartrate (MM120 / LSD) for Post-traumatic stress disorder#

Phase 3ActivePost-traumatic stress disorder indication →

DT120 ODT (formerly MM120; lysergide D-tartrate / LSD) for posttraumatic stress disorder (PTSD) - the third indication after the lead GAD program (Voyage/Panorama) and MDD (Emerge/Ascend). Announced at Definium Therapeutics' April 22, 2026 Investor & Analyst Day as a planned Phase 3 study named 'Haven': ~200 participants randomized 1:1 to a single dose of DT120 ODT vs placebo, primary endpoint change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 8, study initiation expected in 2027. Not yet registered on ClinicalTrials.gov.

Readouts

  • 2027AnticipatedRegistry results

    Phase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027 ↗

Clinical trials#

NCT06809595PanoramaPhase 3Activen=245

Phase 3 Study of MM120 for Generalized Anxiety Disorder (Panorama)

Started Jan 2025· Primary completion Aug 2026· 37 sites across 6 countries

United StatesUnited KingdomFranceGermany

NCT06741228VoyagePhase 3Activen=214

Phase 3 Study of Oral DT120 vs Placebo in Generalized Anxiety Disorder (Voyage)

Started Dec 2024· Primary completion Jul 2026· 34 sites across 1 country

United States

NCT05407064Phase 2Completedn=198

Phase 2b Dose-Finding Study of MM120 for Anxiety Symptoms

Started Aug 2022· Primary completion Oct 2023· 22 sites across 1 country

United States

metprimaryHAM-A change at Week 12 (100 ug vs placebo) — -7.7 points (Cohen's d 0.81) (<0.003)

Clinical response 65%, remission 48% at Week 12.

NCT05200936MMED007Phase 2Completedn=53

Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial

Started Dec 2021· Primary completion Nov 2023· 2 sites across 2 countries

NetherlandsSwitzerland

missedprimaryChange from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at 6 weeks — LSD -7.1 points (95% CI -10.1 to -4.0) vs placebo -8.9 points (95% CI -12.0 to -5.8); AISRS ~37.4->29.6 (LSD) vs ~37.3->29.0 (placebo) (0.7145)

Primary endpoint MISSED. Repeated low-dose MM120 (LSD; 20 ug twice weekly x6 weeks) was not more efficacious than placebo in reducing adult ADHD symptoms on the AISRS at 6 weeks; both arms improved similarly. LSD was psychologically well tolerated and safe in an outpatient setting with no severe adverse effects, but showed no therapeutic advantage over placebo.

NCT06941844EmergePhase 3Recruiting

Phase 3 Study of MM120 (Lysergide) in Major Depressive Disorder (Emerge)

· 25 sites across 1 country

United States

Conference coverage#

MM120 appears in 4 CNS Pulse conference abstracts:

Sources#

  1. Definium Therapeutics (DFTX) maps DT120 ODT Phase 3 readouts and PTSD expansion (8-K) — Definium Therapeutics, Inc.
  2. Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder — Definium Therapeutics, Inc.
  3. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder — Definium Therapeutics
  4. Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder — Definium Therapeutics
  5. Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Apr 22, 2026) — Definium Therapeutics, Inc.
  6. Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares — Definium Therapeutics, Inc.
  7. DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
  8. First patient dosed in Voyage Phase 3 — MindMed / Definium
  9. clinicaltrials.gov — ClinicalTrials.gov
  10. ir.mindmed.co — Reference
Show all 20 sources
  1. Lysergide (LSD), Ligand 17 — IUPHAR/BPS
  2. MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis Fast-Dissolve Technology for Use with MM-120 — MindMed / Definium Therapeutics
  3. MindMed FDA Breakthrough + Phase 2b durability (GAD) — MindMed / Business Wire
  4. MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 — Definium Therapeutics
  5. MM120 Emerge Phase 3 MDD (NCT06941844) — ClinicalTrials.gov
  6. Panorama (NCT06809595) — ClinicalTrials.gov
  7. Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (NCT05200936 / MMED007) — ClinicalTrials.gov
  8. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial — JAMA Psychiatry (Mueller L, et al. 2025;82(6):555-562)
  9. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — JAMA / PMC
  10. Voyage (NCT06741228) — ClinicalTrials.gov